Latest & greatest articles for HIV Exposure

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on HIV Exposure or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on HIV Exposure and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for HIV Exposure

1. Guidance for the use of post-exposure prophylaxis (PEP) for the prevention of HIV in British Columbia

care providers caring for persons who have experienced significant exposure to blood and/or body fluids in the work place or community setting. The risk of Human Immunodeficiency Virus (HIV) acquisition from a given exposure depends on the likelihood the source has transmissible HIV infection, and the biological risk of HIV transmission based on the exposure that has occurred. This guideline is designed to deal specifically with exposures to HIV and is not applicable to other exposures (...) -arv-guidelines/0 Toronto General Hospital, University Health Network Immunodeficiency Clinic. HIV/HCV Drug Therapy Guide. http://app.hivclinic.ca/ 19 XI REFERENCES 1. Kuhar DT, Henderson DK, Struble KA, et al. for the US Public Health Service Working Group. Updated US Public Health Service Guidelines for the Management of Occupational Exposures to Human Immunodeficiency Virus and Recommendations for Postexposure Prophylaxis. Infect Control Hosp Epidemiol 2013; 34: 875-92 2. Centers for Disease

2020 CPG Infobase

2. What methods have been effective in promoting uptake of Pre-exposure prophylaxis (PrEP) among individuals at high risk of HIV, excluding men who have sex with men

What methods have been effective in promoting uptake of Pre-exposure prophylaxis (PrEP) among individuals at high risk of HIV, excluding men who have sex with men Knowledge & Library Services (KLS) Evidence Briefing What methods have been effective in promoting uptake of Pre- exposure prophylaxis (PrEP) among individuals at high risk of HIV, excluding men who have sex with men (MSM), in developed cities comparable to London Nicola Pearce-Smith March 15 th 2019 What methods have been effective (...) Workers/ or Sex Work/ or Drug Users/ or Adolescent/ or Young Adult/ 7. 5 or 6 8. 4 and 7 What methods have been effective in promoting uptake of PrEP among individuals at high risk of HIV KLS Evidence Briefing March 19th 2019 References 1. Koechlin FM, Fonner VA, Dalglish SL, O'Reilly KR, Baggaley R, Grant RM, et al. 2017. Values and Preferences on the Use of Oral Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among Multiple Populations: A Systematic Review of the Literature. Aids Behav 21(5) 1325

2020 Public Health England - Evidence Briefings

3. The efficacy of post-exposure prophylaxis (PEP) for HIV

and nonoccupational postexposure prophylaxis: Updated version, June 13, 2018. Canadian Medical Association Journal. 2017;189(47):E1448–e58. Kuhar DT, Henderson DK, Struble KA, Heneine W, Thomas V, Cheever LW, et al. Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. Infection Control & Hospital Epidemiology. 2013;34(9):875–92. Cardo DM, Culver DH, Ciesielski CA, Srivastava PU, Marcus R (...) after. There was no difference in the rate at which PEP was offered to cases or controls after controlling for HIV transmission risk. However, the odds of HIV seroconversion among health care workers who had received PEP after occupational exposure was reduced by approximately 81%, compared to those who did not receive PEP (4). This study is considered the strongest example of the benefit of PEP in humans (1). Evidence from more recent studies suggests that the administration of antiretroviral

2019 Ontario HIV Treatment Network

4. HIV in pregnancy: Identification of intrapartum and perinatal HIV exposures

HIV in pregnancy: Identification of intrapartum and perinatal HIV exposures The benefits of human immunodeficiency virus (HIV) testing in pregnancy, when combined with appropriate maternal antiretroviral therapy and intrapartum and postnatal prophylaxis, are well established. The vertical rate of transmission of HIV in North America is now well below 2%. Efforts must continue to ensure that these benefits are sustained. Women who have received little or no prenatal care and those who present (...) for delivery with unknown HIV status need immediate testing. As more infants are exposed to antiretroviral agents, strategies need to be implemented to ensure adequate follow-up of these infants. Issues relating to the identification of HIV-exposed infants are highlighted. Keywords: Human immunodeficiency virus; Infant; Intrapartum transmission; Pregnancy; Screening

2019 Canadian Paediatric Society

5. Economic evaluations of pre- and post-exposure prophylaxis for HIV

Columbia Centre for Excellence in HIV/AIDS. HIV post-exposure prophylaxis (PEP) guidelines: May 2017. Available from: Accessed November 30, 2018. Kuhar DT, Henderson DK, Struble KA, Heneine W, Thomas V, Cheever LW, et al. Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. Infection Control Hospital Epidemiology. 2013;34(9):875–92. Hankins C, Macklin R, Warren M. Translating PrEP (...) prophylaxis after sexual or injection-drug exposure to human immunodeficiency virus. Archives of Internal Medicine. 2004;164(1):46–54. Pinkerton SD, Martin JN, Roland ME, Katz MH, Coates TJ, Kahn JO. Cost-effectiveness of HIV postexposure prophylaxis following sexual or injection drug exposure in 96 metropolitan areas in the United States. AIDS. 2004;18(15):2065–73. Herida M, Larsen C, Lot F, Laporte A, Desenclos JC, Hamers FF. Cost-effectiveness of HIV post-exposure prophylaxis in France. AIDS. 2006;20

2019 Ontario HIV Treatment Network

6. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV

Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV UPDATED RECOMMENDATIONS ON FIRST-LINE AND SECOND-LINE ANTIRETROVIRAL REGIMENS AND POST-EXPOSURE PROPHYLAXIS AND RECOMMENDATIONS ON EARLY INFANT DIAGNOSIS OF HIV SUPPLEMENT TO THE 2016 CONSOLIDATED GUIDELINES ON THE USE OF ANTIRETROVIRAL DRUGS FOR TREATING AND PREVENTING HIV INFECTION DECEMBER 2018 INTERIM GUIDELINES HIV TREATMENTUPDATED (...) RECOMMENDATIONS ON FIRST-LINE AND SECOND-LINE ANTIRETROVIRAL REGIMENS AND POST-EXPOSURE PROPHYLAXIS AND RECOMMENDATIONS ON EARLY INFANT DIAGNOSIS OF HIV: INTERIM GUIDELINES SUPPLEMENT TO THE 2016 CONSOLIDATED GUIDELINES ON THE USE OF ANTIRETROVIRAL DRUGS FOR TREATING AND PREVENTING HIV INFECTION DECEMBER 2018WHO/CDS/HIV/18.51 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution- NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https

2019 World Health Organisation HIV Guidelines

7. Effectiveness of oral pre-exposure prophylaxis (PrEP) for HIV

. Knox DC, Anderson PL, Harrigan PR, Tan DH. Multidrug-resistant HIV-1 Infection despite preexposure prophylaxis. New England Journal of Medicine. 2017;376(5):501–2. Montgomery MC, Oldenburg CE, Nunn AS, Mena L, Anderson P, Liegler T, et al. Adherence to pre-exposure prophylaxis for HIV prevention in a clinical setting. PLoS ONE [Electronic Resource]. 2016;11(6):e0157742. Colby DJ, Kroon E, Sacdalan C, Gandhi M, Grant RM, Phanuphak P, et al. Acquisition of multidrug-resistant human immunodeficiency (...) drug-resistant mutations; the underlying cause for this infection remains unclear (15). Authors hypothesise infection with a “wild-type” HIV virus, and that frequent condomless anal sex, potential repeated exposure to HIV, repeated diagnosis of sexually transmitted infections, and the pharmacokinetics of TDF/FTC in rectal mucosa may have contributed to seroconversion (15). Practical considerations While daily oral TDF (with or without FTC) is protective against HIV infection, this is highly

2018 Ontario HIV Treatment Network

8. Effects of adolescent exposure to behaviour change interventions on their HIV risk reduction in Northern Malawi: a situation analysis Full Text available with Trip Pro

Effects of adolescent exposure to behaviour change interventions on their HIV risk reduction in Northern Malawi: a situation analysis Understanding adolescents' translation of HIV and AIDS-related behaviour change interventions (BCI) knowledge and skills into expected behavioural outcomes helps us appreciate behaviour change dynamics among young people and informs evidence-based programming. We explored the effects of adolescents' exposure to BCI on their HIV risk reduction in selected schools (...) model isolated sexual experience ([Beta = .727, p = .0001, p < .05]) as having the strongest correlation with the dependent variable - risk reduction. BCI exposure was stepwise excluded ([Beta = -.082, p = .053, p > .05]). There was therefore no evidence against the null hypothesis of no relationship between adolescent exposure to BCI and their HIV risk reduction. Overall there was limited BCI knowledge and skills translation to behavioural risk reduction. The study points to the need to evaluate

2018 SAHARA J : journal of Social Aspects of HIV/AIDS Research Alliance

9. HIVA/BASHH guidelines on the use of HIV pre-exposure prophylaxis (PrEP)

HIVA/BASHH guidelines on the use of HIV pre-exposure prophylaxis (PrEP) Guideline writing group Michael Brady (Co-chair) Consultant in Sexual Health and HIV, King’s College Hospital, London Alison Rodger (Co-chair) Reader and Honorary Consultant Infectious Diseases and HIV, University College London David Asboe Consultant HIV and Sexual Health, Chelsea and Westminster Hospital NHS Foundation Trust, London Valentina Cambiano Lecturer in Infectious Disease Modelling and Biostatistics, University (...) on the use of HIV pre-exposure prophylaxis (PrEP) 2018 BHIVA/BASHH guidelines on the use of PrEP 2 Contents 1 Objectives 6 1.1 Inclusivity 6 2 Methods 7 2.1 Search strategy 7 2.2 GRADE system 7 2.2.1 Good practice points 8 2.3 Stakeholder involvement, piloting and feedback 8 2.4 Generic preparations of tenofovir disoproxil 8 2.5 References 8 3 Summary of recommendations 9 4 Evidence for safety and efficacy in key populations 15 4.1 Evidence for safety and efficacy in men who have sex with men (MSM) 15

2018 British HIV Association

10. BHIVA/BASHH guidelines on the use of HIV pre-exposure prophylaxis (PrEP)

BHIVA/BASHH guidelines on the use of HIV pre-exposure prophylaxis (PrEP) Guideline writing group Michael Brady (Co-chair) Consultant in Sexual Health and HIV, King’s College Hospital, London Alison Rodger (Co-chair) Reader and Honorary Consultant Infectious Diseases and HIV, University College London David Asboe Consultant HIV and Sexual Health, Chelsea and Westminster Hospital NHS Foundation Trust, London Valentina Cambiano Lecturer in Infectious Disease Modelling and Biostatistics, University (...) on the use of HIV pre-exposure prophylaxis (PrEP) 2018 BHIVA/BASHH guidelines on the use of PrEP 2 Contents 1 Objectives 6 1.1 Inclusivity 6 2 Methods 7 2.1 Search strategy 7 2.2 GRADE system 7 2.2.1 Good practice points 8 2.3 Stakeholder involvement, piloting and feedback 8 2.4 Generic preparations of tenofovir disoproxil 8 2.5 References 8 3 Summary of recommendations 9 4 Evidence for safety and efficacy in key populations 15 4.1 Evidence for safety and efficacy in men who have sex with men (MSM) 15

2018 British Association for Sexual Health and HIV

11. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: interim guidance

is underpinned by two guiding principles: promoting human rights and promoting gender equality. Source: Consolidated guideline on sexual and reproductive health and rights of women living with HIV (3).Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV 6 Fig. 1. Example of an algorithm for programmatic implementation of DTG a TLD (fixed-dose combination of TDF + 3TC + DTG) could be considered (...) Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: interim guidance UPDATED RECOMMENDATIONS ON FIRST-LINE AND SECOND-LINE ANTIRETROVIRAL REGIMENS AND POST-EXPOSURE PROPHYLAXIS AND RECOMMENDATIONS ON EARLY INFANT DIAGNOSIS OF HIV JULY 2018 POLICY BRIEF HIV TREATMENT – INTERIM GUIDANCE @WHO/SEARO Gary HamptonWHO/CDS/HIV/18.18 © World Health Organization 2018 Some rights reserved

2018 World Health Organisation HIV Guidelines

12. Post-exposure HIV prophylaxis

who may have been occupationally or sexually exposed to HIV. Once exposed to HIV, there may be a brief period before the infection is established, during which ART may successfully prevent viral replication. Pinto LA, Landay AL, Berzofsky JA, et al. Immune response to human immunodeficiency virus (HIV) in healthcare workers occupationally exposed to HIV-contaminated blood. Am J Med. 1997;102:21-24. http://www.ncbi.nlm.nih.gov/pubmed/9845492?tool=bestpractice.com Spira AI, Marx PA, Patterson BK, et (...) al. Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. J Exp Med. 1996;183:215-225. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2192425/ http://www.ncbi.nlm.nih.gov/pubmed/8551225?tool=bestpractice.com PEP should be given as soon as possible following exposure; a 28-day course of treatment is recommended. Fisher M, Briggs E, Cresswell F, et al. UK guideline for the use of post-exposure prophylaxis

2018 BMJ Best Practice

13. Tenofovir with emtricitabine for HIV pre-exposure prophylaxis (PrEP)

option for pre-exposure prophylaxis of HIV, now widely available through general practice. 10 min read 17 July 2018 Key points Tenofovir disoproxil with emtricitabine is effective in reducing the incidence of human immunodeficiency virus (HIV) when taken as pre-exposure prophylaxis (PrEP) When compared with placebo, PrEP significantly reduced rates of HIV transmission among adults at medium to high risk of infection. In all study trials, participants also received standard prevention practices (...) This review includes a treatment adherence assessment and tests for HIV and other STIs. Evidence Snapshot What is known about this medicine combination? Tenofovir disoproxil and emtricitabine are frequently used as part of combination antiretroviral therapy for people with human immunodeficiency virus (HIV) infection. Against a background of routine risk-reduction strategies, this combination is also effective in lowering the risk of HIV infection in at-risk populations when taken as pre-exposure

2018 National Prescribing Service Limited (Australia)

14. Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis

of initiation and dura- tion of treatment. J Virol 1998;72:4265-73. 26. Wade NA, Birkhead GS, Warren BL, et al. Abbreviated regimens of zidovudine pro- phylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med 1998;339:1409-14. 27. Mayer KH, Mimiaga MJ, Gelman M, et al. Raltegravir, tenofovir DF, and emtric- itabine for postexposure prophylaxis to prevent the sexual transmission of HIV: safety, tolerability, and adherence. J Acquir Immune Defic Syndr 2012;59:354-9. 28 (...) the potential for higher-quality data in humans. nPEP is not recommended for individuals who have had a low- risk exposure, regardless of source HIV status. We also do not rec- ommend nPEP for those who have had a moderate-to-high risk exposure from a source individual who is known to be HIV positive but is documented to be virologically suppressed on antiretroviral therapy, and who does not have a known concomitant STI. Of note, all PEP use is off label in Canada. We recommend beginning nPEP as soon

2017 CPG Infobase

15. Occupational exposure, attitude to HIV-positive patients and uptake of HIV counselling and testing among health care workers in a tertiary hospital in Nigeria Full Text available with Trip Pro

Occupational exposure, attitude to HIV-positive patients and uptake of HIV counselling and testing among health care workers in a tertiary hospital in Nigeria Health care workers (HCWs) are at risk of occupational exposure to HIV. Their attitude to HIV-positive patients influences patients' willingness and ability to access quality care. HIV counselling and testing (HCT) services are available to inform HCWs and patients about their status. There is little information about HCT uptake (...) and attitude to HIV-positive patients among HCWs in tertiary health facilities in Nigeria. The aim of this study was to determine occupational exposure and attitude to HIV-positive patients and level of uptake of HCT services among HCWs in a tertiary hospital in Nigeria. A cross-sectional design was utilized. A total of 977 HCWs were surveyed using semi-structured, self-administered questionnaires. Nurses and doctors comprised 78.2% of the respondents. Their mean age was 35 ± 8.4 years. Almost half, 47.0

2017 SAHARA J : journal of Social Aspects of HIV/AIDS Research Alliance

16. HIV Pre-Exposure Prophylaxis with Emtricitabine/Tenofovir Disoproxil Fumarate — Regulatory and Reimbursement Policies

of high-risk sexual encounters — precautions that may not be accepted by some individuals. This situation changed in 2012 with the FDA approval and availability of the fixed-dose antiviral combination emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) Truvada, manufactured by Gilead, for HIV pre-exposure prophylaxis (PrEP) in the US. Taking the antivirals once daily lowers the likelihood of HIV establishing a productive infection in the human host. 4 Clinical trials have shown this treatment (...) préexposition au virus de l'immunodéficience humaine [Internet]. Québec (QC): Ministère de la Santé et des Services sociaux; 2013. [cited 2016 Dec 9]. Available from: US Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States - 2014 [Internet]. Atlanta (Georgia): Centres for Disease Control; 2014. [cited 2016 Dec 20]. Available from: Commonwealth of Massachusetts. Frequently Asked Questions: Pre-exposure prophylaxis (PrEP) for HIV infection [Internet]. Boston

2017 Canadian Agency for Drugs and Technologies in Health - Environmental Scanning

17. HIV Pre-Exposure Prophylaxis with Emtricitabine/Tenofovir Disoproxil Fumarate — Regulatory and Reimbursement Policies

of high-risk sexual encounters — precautions that may not be accepted by some individuals. This situation changed in 2012 with the FDA approval and availability of the fixed-dose antiviral combination emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) Truvada, manufactured by Gilead, for HIV pre-exposure prophylaxis (PrEP) in the US. Taking the antivirals once daily lowers the likelihood of HIV establishing a productive infection in the human host. 4 Clinical trials have shown this treatment (...) préexposition au virus de l'immunodéficience humaine [Internet]. Québec (QC): Ministère de la Santé et des Services sociaux; 2013. [cited 2016 Dec 9]. Available from: US Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States - 2014 [Internet]. Atlanta (Georgia): Centres for Disease Control; 2014. [cited 2016 Dec 20]. Available from: Commonwealth of Massachusetts. Frequently Asked Questions: Pre-exposure prophylaxis (PrEP) for HIV infection [Internet]. Boston

2017 Canadian Agency for Drugs and Technologies in Health - Environmental Scanning

18. Emtricitabine/Tenofovir for Post-Exposure Prophylaxis Against HIV: A Review of Clinical Effectiveness and Cost-Effectiveness

Emtricitabine/Tenofovir for Post-Exposure Prophylaxis Against HIV: A Review of Clinical Effectiveness and Cost-Effectiveness Emtricitabine/Tenofovir for Post-Exposure Prophylaxis Against HIV: A Review of Clinical Effectiveness and Cost-Effectiveness | CADTH.ca Find the information you need Emtricitabine/Tenofovir for Post-Exposure Prophylaxis Against HIV: A Review of Clinical Effectiveness and Cost-Effectiveness Emtricitabine/Tenofovir for Post-Exposure Prophylaxis Against HIV: A Review (...) of Clinical Effectiveness and Cost-Effectiveness Published on: March 17, 2017 Project Number: RC0868-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of emtricitabine/tenofovir, with or without integrase strand transfer inhibitors, compared with alternative antiretroviral drug regimens for post-exposure prophylaxis against HIV? What is the cost-effectiveness of emtricitabine/tenofovir, with or without

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

19. WHO implementation tool for pre-exposure prophylaxis (PrEP) of HIV infection: module 1: clinical

WHO implementation tool for pre-exposure prophylaxis (PrEP) of HIV infection: module 1: clinical WHO implementation tool for pre-exposure prophylaxis (‎PrEP)‎ of HIV infection: module 1: clinical JavaScript is disabled for your browser. Some features of this site may not work without it. Toggle navigation Toggle navigation Search Browse Statistics Related Links WHO implementation tool for pre-exposure prophylaxis (‎PrEP)‎ of HIV infection: module 1: clinical View/ Open Rights View Statistics (...) Altmetrics Share Citation World Health Organization . (‎2017)‎. WHO implementation tool for pre-exposure prophylaxis (‎PrEP)‎ of HIV infection: module 1: clinical. World Health Organization. . License: CC BY-NC-SA 3.0 IGO Description 28 p. Gov't Doc # WHO/HIV/2017.17 Collections Language English Metadata Related items Showing items related by title and MeSH subject.  World Health Organization (‎ WHO/HIV/2017.25 , 2017 )‎  World Health Organization (‎ WHO/HIV/2017.24 , 2017 )‎  World Health

2017 WHO

20. WHO implementation tool for pre-exposure prophylaxis (PrEP) of HIV infection

WHO implementation tool for pre-exposure prophylaxis (PrEP) of HIV infection WHO implementation tool for pre-exposure prophylaxis (‎PrEP)‎ of HIV infection JavaScript is disabled for your browser. Some features of this site may not work without it. Toggle navigation Toggle navigation Search Browse Statistics Related Links WHO implementation tool for pre-exposure prophylaxis (‎PrEP)‎ of HIV infection View/ Open Rights View Statistics Altmetrics Share Citation World Health Organization . (‎2017 (...) )‎. WHO implementation tool for pre-exposure prophylaxis (‎PrEP)‎ of HIV infection. World Health Organization. . License: CC BY-NC-SA 3.0 IGO Description 2 p. Gov't Doc # WHO/HIV/2017.19 Collections Language English Metadata Related items Showing items related by title and MeSH subject.  World Health Organization (‎ WHO/HIV/2017.25 , 2017 )‎  World Health Organization (‎ WHO/HIV/2017.24 , 2017 )‎  World Health Organization (‎ WHO/HIV/2017.26 , 2017 )‎ View Item

2017 WHO